Anti-SFRP4 antibody (bs-1331R)

Anti-SFRP4 antibody

DATASHEET

Host:Rabbit

Target Protein:SFRP4

IR:Immunogen Range:151-260/351

Clonality:Polyclonal

Isotype:IgG

Entrez Gene:6424

Swiss Prot:Q6FHJ7

Source:KLH conjugated synthetic peptide derived from human sFRP-4:151-260/351 

Purification:affinity purified by Protein A

Storage:0.01M TBS(pH7.4) with 1% BSA, 0.03% Proclin300 and 50% Glycerol. Shipped at 4℃. Store at -20 °C for one year. Avoid repeated freeze/thaw cycles.

Background:Soluble frizzled-related proteins (sFRPS) function as modulators of Wnt signaling through direct interaction with Wnts. They have a role in regulating cell growth and differentiation in specific cell types. SFRP4 may act as a regulator of adult uterine morphology and function. Increases apoptosis during ovulation possibly through modulation of FZ1/FZ4/WNT4 signaling Has phosphaturic effects by specifically inhibiting sodium-dependent phosphate uptake. [SUBCELLULAR LOCATION] Secreted. Expressed in mesenchymal cells. Highly expressed in the stroma of proliferative endometrium. Expressed in cardiomyocytes. Belongs to the secreted frizzled-related protein (sFRP) family.

Size:100ul

Concentration:1mg/ml

Applications:WB(1:500-2000)
ELISA(1:5000-10000)
IHC-P(1:100-500)
IHC-F(1:100-500)
IF(1:100-500)

Cross Reactive Species:Human
Mouse
Rat
Dog
Pig
Cow
Rabbit
.

For research use only. Not intended for diagnostic or therapeutic use.

VALIDATION IMAGES

Sample:
Bone (Mouse) Lysate at 40 ug
Primary: Anti-SFRP4 (bs-1331R) at 1/300 dilution
Secondary: IRDye800CW Goat Anti-Rabbit IgG at 1/20000 dilution
Predicted band size: 38 kD
Observed band size: 60 kD

Tissue/cell: human colon cancer; 4% Paraformaldehyde-fixed and paraffin-embedded;
Antigen retrieval: citrate buffer ( 0.01M, pH 6.0 ), Boiling bathing for 15min; Block endogenous peroxidase by 3% Hydrogen peroxide for 30min; Blocking buffer (normal goat serum,C-0005) at 37℃ for 20 min;
Incubation: Anti-sFRP-4 Polyclonal Antibody, Unconjugated(bs-1331R) 1:200, overnight at 4°C, followed by conjugation to the secondary antibody(SP-0023) and DAB(C-0010) staining